EUROAPI Announces Appointment of Tristan Imbert to the Board of Directors
EUROAPI has co-opted Tristan Imbert as an Independent Director following the resignation of Rodolfo Savitzky.
Resignation and Appointment
According to a press release issued on December 10, 2025, EUROAPI announced the resignation of Rodolfo Savitzky from his position as Independent Director, effective December 31, 2025. Following the recommendation of the Nomination and Remuneration Committee, the Board of Directors decided to co-opt Tristan Imbert as his replacement. His appointment is subject to approval by the General Meeting of shareholders scheduled for May 27, 2026.
Professional Background of Tristan Imbert
Tristan Imbert began his career in research and development at Sanofi Aventis. He later worked for the Boston Consulting Group, advising clients in the pharmaceutical industry in New York and Paris, before joining Novartis in 2005. There, he held several financial management positions, culminating as the Financial Director of Novartis Gene Therapies. More recently, in 2021, he became the Financial Director of Cimeio Therapeutics. Imbert holds a master's degree in applied mathematics from the University of Paris-Sud and an MBA from Columbia University.
Comments from the Chairman
Emmanuel Blin, Chairman of EUROAPI, expressed his enthusiasm about the appointment of Tristan Imbert, highlighting that his expertise in finance, R&D, and strategy will be valuable to the Board. Additionally, the company thanked Rodolfo Savitzky for his contributions during his three years as a member of the Board and Chairman of the Audit Committee.
